No Detail Found!

Has the COVID-19 Pandemic Increased Mortality Among Patients with Cancer Receiving Systemic Anticancer Treatments?

Author(s)
Ay_e Demirci Department of Medical Oncology, Sakarya University Training and Research Hospital,Sakarya,Turkey
Cemil Bilir Department of Medical Oncology, Sakarya University Training and Research Hospital,Sakarya,Turkey
Emre Cakir Department of Medical Oncology, Sakarya University Training and Research Hospital,Sakarya,Turkey
Burcu Gulbagci Department of Medical Oncology, Sakarya University Training and Research Hospital,Sakarya,Turkey
Ilhan Hacibekiroglu Department of Medical Oncology, Sakarya University Training and Research Hospital,Sakarya,Turkey
Ceyhun Varim Department of Internal Medicine, Sakarya University Training and Research Hospital,Sakarya,Turkey
Abstract
Objective: To evaluate the mortality rates in patients receiving anticancer therapy in the coronavirus disease-19 (COVID-19) pandemic period. Study Design: Descriptive study. Place and Duration of Study: Department of Medical Oncology, Sakarya University Training and Research Hospital, Sakarya, Turkey, from December 2017 to May 2020. Methodology: Only patients who received chemotherapy and immunotherapy were selected and enrolled in the study. All patients (n=3,204) were divided into three groups, namely the rst group (1st December 2017-31st May 2018, n=918), second group (1st December 2018-31st May 2019, n=1,147), and the pandemic period group (PPG) (1st December 2019-31st May 2020, n=1,139), according to the period during which they received anticancer treatment. The clinical and demographic characteristics and mortality rates of these three groups of patients were compared. Results: The median age of the total of 3,204 patients was 61 (53-69). In this study, 51.1% (n=1,636) were females and 48.9% were males. The mortality rates were 13.5% (n=124) in the rst group, 13.4% (n=154) in the second group, and 13.0% (n=148) in the PPG, respectively. Overall mortality rates did not di er among patients with cancer in the three di erent six-month periods analysed (p = 0.931). Conclusion: There was no unexpected increased in mortality rate among patients undergoing cancer therapy during the COVID-19 pandemic as compared to the previous years of the same timeline. No increase in monthly mortality rates among patients receiving anti-cancer treatment were demonstrated during the pandemic period.
Publication Details
Page(s) 66-70
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 31, Issue: S2, Year: 2021

Request the full text from PASTIC

Keywords
COVID-19, Mortality, Cancer, Pandemic, Anticancer therapy
0

Citations

0

Downloads

94

Views